Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Polyphor completes Phase I study of transplant drug
The trial was conducted by Covance, and involved 74 healthy volunteers enrolled in the UK. The primary objective of this Phase I clinical trial was to demonstrate that
The trial was conducted by Covance, and involved 74 healthy volunteers enrolled in the UK. The primary objective of this Phase I clinical trial was to demonstrate that
The project is part of the EuroTransBio Initiative and is coordinated by the Dutch company Crossbeta Biosciences. The objective is the development of novel vaccine technologies based on
Viren Grover, vice-chairman of Pinnacle Biologics, said: “We are pleased to conclude this agreement with Pharmexx, which allows us a cost effective way to support our sales and
This represents a purchase price of CHF130 per registered share. Following the closing of the agreement with Speedel’s major shareholders, Novartis, including the 9.7% stake in Speedel prior
Chenofalk is approved in Germany for the dissolution of gallstones, and Sigma-Tau’s German affiliate, Sigma-Tau Arzneimittel, will immediately assume distribution of this important medicine, ensuring there is no
Zinthionein capsules (25mg capsules twice daily) were compared to placebo capsules twice daily on a 1:1 randomization scheme in a prospective, randomized, double-blind, placebo-controlled trial involving a total
The new Phase I clinical trial will examine the safety and immunological response of breast and ovarian cancer patients to a combination of AE37 plus a peptide vaccine
The purchase price will be paid in two installments, $7 million at closing and $3 million six months after closing. At the election of the company, up to
According to the company, the spinal replacement disc for the spine mimics the functionality of the patient’s own intervertebral disc and can be put into place by the
The complaint – filed in the Supreme Court of the State of New York – alleges, among other things, that Protein Sciences (PSC) and its senior management engaged